cannabis d'souza

THC

responsible for euphoria, produce dependence, withdrawal, highly lipophilic, crosses BBB, poor oral bioavailability, hepatic metabolism, long half life, hihg binding affinity

CBD

no euphoria, causes fatigue and somnolence, low affinity

which product has highest THC content

Kief

2 main endogenous ligands

anandamide, 2-arachidonoglycol, olvanil

endocannabinoids are degraded to

arachidonic acid, glycol, ethanolamide

CB1+2 receptors are coupled to

GPCR

activation of CB receptors results in __

decreased production of cAMP

CB1

abundant in CNS, CV tissues, GI tract, liver, bones, skin, reproductive system

CB2

less in CNS, neurons and glia, mainly on peripheral tissue, immune cells, macrophages, blood cells, liver tissue, pancreas, bone

ways to manipulate endogenous cannabinoid system

increase synthesis of endogenous ligand, target cannabinoid receptors, target enzymes that degrade cannabinoids, target transporters that terminate action of endogenous cannabinoids

low dose acute effects of cannabis

euphoria, relaxation, hunger, talkativeness, laughing, perceptual disturbances, decreased psychomotor activity, impaired driving

high dose cannabis effects

panic, anxiety, dizziness, headache, paraesthesia,tremor, rare seizures

chronic cannabis toxicity/effects

increased risk of schizophrenia, amotivational syndrome, depression, cognitive impairment, chronic cough, increased risk of infection, cancer risk, immune suppression, tachycardia, ortho hypo, decreased release of pituitary hormones, increased release of cortisol, reproductive effects

effects of withdrawal

insomnia, anorexia, anxiety, irritability, depression, tremor

symptoms of withdrawal peak in __ and last up to _

first week, 2 weeks

tx

no FDA approved tx, manage acute withdrawal using sedatives, treat underlying psych disorders and other substance use issues

s/s of synthetic cannabinoid intoxication

agitation, hallucination, chest pain, nausea/vomiting, SOB, renal failure, reduced T cell function

therapeutic uses for cannabis

antiemetic, appetite stimulant, anticonvulsant, movement disorders, MS spacisity, analgesia, glaucoma, insomnia, anxiety, depression

challenges with widespread cannabis use

addictive, gateway drug, vulnerable populations, abuse